Apixaban in Obese Patients

Please use landscape view or desktop screen to view the content.

Outcomes

Primary: Ischemic stroke with or without hemorrhagic conversion
Secondary: Systemic embolic events (symptomatic DVT, PE, or arterial thrombosis) and bleeding
(ISTH major or CRNM)

Included

Patients aged ≥18 years with a BMI ≥50 kg/m² and NVAF initiated on apixaban or rivaroxaban between
Jan 2013 and Sep 2019*

Excluded

Pregnancy; incarceration; hypercoagulable disorder diagnosis^†

*Initiation of therapy included the first prescription of apixaban or rivaroxaban if initiation occurred outpatient, or the date of initiation of apixaban or rivaroxaban if during hospitalization.
^†Antiphospholipid syndrome, protein C deficiency, protein S deficiency, antithrombin deficiency, factor V Leiden, congenital thrombophilia, and hereditary and acquired thrombophilia.

BMI, body mass index; CRNM, clinically relevant non-major; DVT, deep vein thrombosis; ISTH, International Society on Thrombosis and Haemostasis; NVAF, non-valvular atrial fibrillation; PE, pulmonary embolism.

Methods1

Methods¹